Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B Clinical Trial

Official title: Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Status Terminated

Clinical Trial Summary

The purpose of this study was to assess the safety and tolerability of multiple doses of a human monoclonal antibody (BAY1093884) given under the skin in subjects with hemophilia A or B. This antibody was intended to protect from bleeds by inhibiting a substance (Tissue Factor Pathway Inhibitor, TFPI) that reduces the ability of the body to form blood clots.

Clinical Trial Description

The primary objective of the study was to assess the safety and tolerability of multiple subcutaneous injections of BAY1093884 (anti-TFPI monoclonal antibody, immunoglobulin G2, IgG2) in patients with hemophilia A or B with or without inhibitors. ;

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia A and B

• NCT number: NCT03597022
• Study type: Interventional
• Source: Bayer
• Status: Terminated
• Phase: Phase 2
• Start date: July 24, 2018
• Completion date: October 15, 2019